Publication of First Results in Ongoing Malaria Vaccine Trial Marks Important Milestone
Initial results from ongoing Phase 3 efficacy trial show that the RTS,S malaria vaccine candidate reduces malaria by half in African children 5–17 months old, after 12 months of follow-up. Read more »
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.
Our portfolio
We maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.
What we do and how we do it
We provide funding and technical support to partners worldwide to accelerate the development of malaria vaccines. We also work to ensure that malaria vaccines will reach those who need them.
Malaria deaths down, but progress fragile, says WHO
Malaria deaths have fallen by more than 25 percent globally since 2000 and by 33 percent in Africa, says the World Malaria Report 2011 of the World Health Organization (WHO). However, projected funding shortfall threatens gains.
TIME article names RTS,S in the top 10 medical breakthroughs of 2011.
MVI collaborates with National Institute of Allergy and Infectious Diseases and Johns Hopkins
Partnership to evaluate potential vaccine candidate designed to prevent malaria transmission from mosquitoes to humans.
First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children
First results from a large-scale Phase 3 trial of RTS,S, published online in the New England Journal of Medicine (NEJM).
Twitter
Flickr